Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

Alzheimer Disease Clinical Trial

Official title:

Beta Amyloid PET Imaging for Alzheimer Disease: [18F]-Fluselenamyl (Alternative Vehicle) Comparison With [11C]-PIB (FSA-PIB AD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06439992
• Other study ID #: FSA-PIB AD
• Status: Recruiting
• Start date: November 7, 2023
• Est. completion date: November 2025

Study information

• Verified date: May 2024
• Source: Washington University School of Medicine
• Contact: Jayashree Rajamanickam
• Phone: 314 273 6140
• Email: jayashree.r[@]wustl.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.

Description:

The investigators will first complete whole-body PET dosimetry studies in healthy adult normal volunteers to calculate the actual radiation dose of each human organ and determine the allowable dose for a human subject when receiving a single dose for a PET scan.

Second, imaging of the brain and neck will be completed in a wide range of ages of healthy adult normal control participants and participants with mild cognitive impairment, both male and females to characterize 18F-Fluselenamyl uptake in the brain, its binding to beta-amyloid plaques, and radiolabeled metabolite will be completed. Amyloid is a protein related to dementia of Alzheimer's disease. 11C-PIB PET imaging and MRI of the brain will also be completed in the same participants and the data will be compared with 18F-Fluselenmayl. 11C-PIB and 18F-Fluselenamyl both bind to beta-amyloid plaques.

Finally, a comparison of the normal control participants to patients with Alzheimer's disease will be completed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: November 2025
• Est. primary completion date: November 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or Female, any race

• Age = 18 years

• Healthy volunteers or volunteers with Alzheimer's disease

Exclusion Criteria:

• Has hypersensitivity to 18F-Fluselenamyl or any of its excipients ;

• Has hypersensitivity to 11C-PIB or any of its excipients ;

• Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;

• Unwilling or unable to undergo PET scans tracer injections ;

• Unwilling or unable to undergo MRI (Aim 2 and Aim 3)

• Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer);

• Women who are currently pregnant or breast-feeding;

• Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1.

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• 18F-Fluselenamyl
Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety of the new formulation of Fluselenamy PET Imaging in 8 healthy adult normal volunteers.	Whole-body PET/CT images (skull vertex to proximal thighs) will be obtained in 8 healthy volunteers (4 males and 4 females) for up to a maximum of 4.5 hours immediately following intravenous (IV) injection of 10 mCi ± 20% of [18F]-Fluselenamyl (dosage range calculated from rodent dosimetry data extrapolated to humans).; The primary outcome measure is to quantify each organ's radiation exposure (rad/mCi).	Through study completion, an average of 1 year
Primary	PET imaging of [18F]-Fluselenamyl in healthy normal control participants and participants with mild cognitive impairment.	To assess the sensitivity of [18F]-Fluselenamyl to image Amyloid beta in the setting of mild cognitive impairment, and conduct a comparative analysis of PET imaging data using [11C]-PIB imaging in the same participants.	Through study completion, an average of 2 years